161 related articles for article (PubMed ID: 38555544)
1. Authorized or Off-Label Use? A Structured Analysis of Summaries of Product Characteristics with Regard to Authorization in Pediatrics.
Herzig M; Eisenhofer S; Ruschkowski M; Neubert A; Bertsche A; Bertsche T; Neininger MP
Pharmaceut Med; 2024 May; 38(3):205-216. PubMed ID: 38555544
[TBL] [Abstract][Full Text] [Related]
2. Unlicensed and off-label uses of medicines: definitions and clarification of terminology.
Aronson JK; Ferner RE
Br J Clin Pharmacol; 2017 Dec; 83(12):2615-2625. PubMed ID: 28779556
[TBL] [Abstract][Full Text] [Related]
3. Information in summaries of product characteristics about use in children is limited and needs standardisation: a systematic analysis in Switzerland.
Tilen R; Berger C; Allemann S; Meyer Zu Schwabedissen H
Arch Dis Child; 2024 Jun; 109(7):586-591. PubMed ID: 38448199
[TBL] [Abstract][Full Text] [Related]
4. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
5. The Quality and Reliability of Information in the Summaries of Product Characteristics.
Drelich E; Religioni U; Chung K; Kaźmierczak J; Blicharska E; Neumann-Podczaska A; Krysiński J; Merks P
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206371
[TBL] [Abstract][Full Text] [Related]
6. [Medicines for children and "off-label use" 5 years after implementation of the Paediatric Regulation (EC) No 1901/2006. An interim analyis].
Afentaki A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Sep; 57(9):1111-9. PubMed ID: 25139386
[TBL] [Abstract][Full Text] [Related]
7. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
8. More medicines for children: impact of the EU paediatric regulation.
Nordenmalm S; Tomasi P; Pallidis C
Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
[TBL] [Abstract][Full Text] [Related]
9. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
Beers E; Egberts TC; Leufkens HG; Jansen PA
Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
[TBL] [Abstract][Full Text] [Related]
10. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
11. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.
Weersink RA; Timmermans L; Monster-Simons MH; Mol PGM; Metselaar HJ; Borgsteede SD; Taxis K
Front Pharmacol; 2019; 10():1031. PubMed ID: 31607904
[No Abstract] [Full Text] [Related]
12. Drug utilization and off-label drug use in Spanish pediatric gastroenterology outpatients.
Ruíz-Antorán B; Piñeiro R; Avendaño C; Román E; Cilleruelo ML; Gutiérrez-Junquera C; Centeno G; Cilleruelo MJ
J Pediatr Gastroenterol Nutr; 2013 Feb; 56(2):173-7. PubMed ID: 23328455
[TBL] [Abstract][Full Text] [Related]
13. Harmonization of summaries of product characteristics (SmPCs) of drugs with the same active ingredients: an evaluation of SmPCs of the most frequently prescribed active substances.
Gahr M; Connemann BJ; Muche R; Zeiss R; Wolf A
Eur J Clin Pharmacol; 2022 Mar; 78(3):419-434. PubMed ID: 34705065
[TBL] [Abstract][Full Text] [Related]
14. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey.
Palčevski G; Skočibušić N; Vlahović-Palčevski V
Eur J Clin Pharmacol; 2012 Jul; 68(7):1073-7. PubMed ID: 22307225
[TBL] [Abstract][Full Text] [Related]
15. Who are the PDCO?
Dempsey EM; Connolly K
Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
[TBL] [Abstract][Full Text] [Related]
16. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing dosing changes in the label of biologicals.
Minnema LA; Giezen TJ; Gardarsdottir H; Egberts TCG; Leufkens HGM; Mantel-Teeuwisse AK
Br J Clin Pharmacol; 2019 Apr; 85(4):715-721. PubMed ID: 30593087
[TBL] [Abstract][Full Text] [Related]
18. Off-label drug prescribing in a Portuguese paediatric emergency unit.
Ribeiro M; Jorge A; Macedo AF
Int J Clin Pharm; 2013 Feb; 35(1):30-6. PubMed ID: 23054136
[TBL] [Abstract][Full Text] [Related]
19. Pediatric psychopharmacological research in the post EU regulation 1901/2006 era.
Schmäl C; Becker K; Berg R; Brünger M; Lehmkuhl G; Oehler KU; Ruppert T; Staudter C; Trott GE; Dittmann RW
Z Kinder Jugendpsychiatr Psychother; 2014 Nov; 42(6):441-9. PubMed ID: 25335522
[TBL] [Abstract][Full Text] [Related]
20. Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.
Tonkovic B; Rutishauser LK
J Manag Care Spec Pharm; 2014 Apr; 20(4):357-67. PubMed ID: 24684640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
